Drug Search Results

Emixustat

Alternative Names: emixustat, acu-4429
Latest Update: 2024-05-30
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: RPE65 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Orphan Drug - Stargardt Disease *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Kubota Vision
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Emixustat

Countries in Clinic: Brazil, Canada, Denmark, France, Germany, Italy, Netherlands, South Africa, Spain, United Kingdom, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Macular Degeneration|Stargardt Disease

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
SeaSTAR	P3	Completed	Stargardt Disease\|Macular Degeneration	2022-06-13

Recent News Events

Date	Type	Title
10/04/2023	News Article	Smart Health Watches Market to Observe Prominent USD 185.63 Billion Growth by 2029
10/04/2023	News Article	Radiology Information Systems (RIS) Market to Notice Prominent USD 1,782.5 Million Growth by 2029
09/27/2023	PubMed	Updates on Emerging Interventions for Autosomal Recessive ABCA4-Associated Stargardt Disease.
07/01/2023	PubMed	Computational attributes of protein kinase-C gamma C2-domain & virtual screening for small molecules: elucidation from meta-dynamics simulations & free-energy calculations.
06/22/2023	PubMed	Tuning the Metabolic Stability of Visual Cycle Modulators through Modification of an RPE65 Recognition Motif.
05/15/2023	News Article	ABCA4 Retinopathy Therapeutics Market Will Register a CAGR of 18.6% from 2023 to 2031, says Growth Plus Reports
07/27/2022	News Article	Kubota Vision Announces Database Lock for Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease and Expected Release of Top-Line Results in August 2022

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions